Circulation, 146, 657-672 Circulation : an official journal of the American Heart Association / ed.-in-chief Ephraim Donosco 146(9), 657-672 (2022). doi:10.1161/CIRCULATIONAHA.121.057807 Hagström, E, Steg, P G, Szarek, M, Bhatt, D L, Bittner, V A, Danchin, N, Diaz, R, Goodman, S G, Harrington, R A, Jukema, J W, Liberopoulos, E, Marx, N, McGinniss, J, Manvelian, G, Pordy, R, Scemama, M, White, H D, Zeiher, A M, Schwartz, G G, ODYSSEY OUTCOMES Investigators & Bøttcher, M 2022, ' Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab ', Circulation, vol. 146, no. 9, pp. 657-672 . https://doi.org/10.1161/CIRCULATIONAHA.121.057807 Circulation, vol 146, iss 9 Circulation, 146, 9, pp. 657-672 Circulation, Philadelphia : Lippincott Williams & Wilkins, 2022, vol. 146, iss. 9, p. 657-672 Circulation, 146(9), 657-672. LIPPINCOTT WILLIAMS & WILKINS
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
Vallejo-Vaz, A J, Stevens, C A T, Lyons, A R M, Dharmayat, K I, Freiberger, T, Hovingh, G K, Mata, P, Raal, F J, Santos, R D, Soran, H, Watts, G F, Abifadel, M, Aguilar-Salinas, C A, Alhabib, K F, Alkhnifsawi, M, Almahmeed, W, Alnouri, F, Alonso, R, Al-Rasadi, K, Al-Sarraf, A, Al-Sayed, N, Araujo, F, Ashavaid, T F, Banach, M, Béliard, S, Benn, M, Binder, C J, Bogsrud, M P, Bourbon, M, Chlebus, K, Corral, P, Davletov, K, Descamps, O S, Durst, R, Ezhov, M, Gaita, D, Genest, J, Groselj, U, Harada-Shiba, M, Holven, K B, Kayikcioglu, M, Khovidhunkit, W, Lalic, K, Latkovskis, G, Laufs, U, Liberopoulos, E, Lima-Martinez, M M, Nordestgaard, B G, Tybjærg-Hansen, A, Chen, Y & EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) 2021, ' Global perspective of familial hypercholesterolaemia : a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) ', The Lancet, vol. 398, no. 10312, pp. 1713-1725 . https://doi.org/10.1016/S0140-6736(21)01122-3
Journal of the American College of Cardiology, 78(5), 421-433. ELSEVIER SCIENCE INC Journal of The American College of Cardiology, New York : Elsevier Biomedical, 2021, vol. 78, no. 5, p. 421-433 Repositorio Universidad de Santander Universidad de Santander instacron:Universidad de Santander Schwartz, G G, Szarek, M, Bittner, V A, Diaz, R, Goodman, S G, Jukema, J W, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R, Scemama, M, Sinnaeve, P, White, H D, Gabriel Steg, P, Gabriel Steg, P H, Bhatt, D L, Harrington, R A, Zeiher, A M, Tricoci, P, Roe, M T, Mahaffey, K W, Edelberg, J M, Hanotin, C, Lecorps, G, Moryusef, A, Sasiela, W J, Tamby, J F, Aylward, P E, Drexel, H, Sinnaeve, P, Dilic, M, Lopes, R D, Gotcheva, N N, Prieto, J C, Yong, H, Pećin, I, Reiner, Z, Clemmensen, P, Bang, L E, Hove, J D, Gislason, G, Larsen, J, Johansen, P, Jeppesen, J, Nielsen, P K, Hansen, O, Jensen, S A, Rosenberg, M, Andersen, D & ODYSSEY OUTCOMES Committees and Investigators 2021, ' Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol ', Journal of the American College of Cardiology, vol. 78, no. 5, pp. 421-433 . https://doi.org/10.1016/j.jacc.2021.04.102 Schwartz, G G, Szarek, M, Bittner, V A, Diaz, R, Goodman, S G, Jukema, J W, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R, Scemama, M, Sinnaeve, P, White, H D, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2021, ' Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol ', Journal of the American College of Cardiology, vol. 78, no. 5, pp. 421-433 . https://doi.org/10.1016/j.jacc.2021.04.102 Journal of the American College of Cardiology, vol 78, iss 5
RECOVERY Collaborative Group & Downey, D 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 LANCET Mumford, A, Ramanan, A V & Gibbison, B J J & Welch, H F 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5, https://doi.org/10.1016/S0140-6736(21)00149-5 The Lancet RECOVERY Collaborative Group, Felton, T, Evans, D G, Murray, C, Buch, M & Dark, P 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5
Repositorio Universidad de Santander Universidad de Santander instacron:Universidad de Santander Circulation Circulation, 140(19), 1578-1589. LIPPINCOTT WILLIAMS & WILKINS Roe, M T, Li, Q H, Bhatt, D L, Bittner, V A, Diaz, R, Goodman, S G, Harrington, R A, Jukema, J W, Lopez-Jaramillo, P, Lopes, R D, Louie, M J, Moriarty, P M, Szarek, M, Vogel, R, White, H D, Zeiher, A M, Baccara-Dinet, M T, Steg, P G, Schwartz, G G, ODYSSEY OUTCOMES Committees and Investigators, Gislason, G, Davidsen, F & Videbaek, L 2019, ' Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes ', Circulation, vol. 140, no. 19, pp. 1578-1589 . https://doi.org/10.1161/CIRCULATIONAHA.119.042551 Circulation, 140(19), 1578-1589. Lippincott Williams & Wilkins